Download the ESMO 2012 Abstract Book - Oxford Journals

Annals of Oncology
58% were female and 42% were male. Incidence of breast cancer in female were
predominant (29.99%), followed by cervical carcinoma (23.99%). Tobacco habits
predominated among 80% of males and 20% of females. Hence oral cancer was the
most common (35.98%) amongst men, followed by lung cancer (29.98 %).
Conclusion: The results showed a strong association of overweight and obesity with
cancer in this group primarily due to life style, dietary and smoking habits. Hence
some minor lifestyle choices which encompasses dietary restriction of calorie/fat
intake and avoiding animal protein especially red meat, cessation of tobacco and
alcohol intake, exercising and maintaining an ideal body-mass index, healthy body
weight and composition through a diet rich in fruits and green vegetables reduces the
risk of cancer.
Disclosure: All authors have declared no conflicts of interest.
1376P NEXT GENERATION CANCER REGISTRY; OPPORTUNITIES
OF WEB 3.0 AND PHYSICIAN PERSPECTIVE
A.S. Alfaar, M. Kamal, M. Sabry
Research Department, Children’s Cancer Hospital Egypt, Cairo, EGYPT
Background: Cancer registry is a systematic data collection about cancer incidents.
They are either population based or hospital based (also known as center based)
cancer registries. Population-based cancer registries can help in building hypotheses
about cancer shared risk factors in contrast with hospital-based registries which focus
more on improving quality of therapy. Standardizing documentation and
communication methods fosters collaboration between different regional institutes for
building a national cancer registry. In our study we aim at demonstrating how recent
Web 3.0 technologies can help cancer registries.
Material and methods: We started by studying the available information technology
resources by qualified researchers who work on analyzing clinical research needs.
We’ve developed a system analysis after studying paper and computer-based cancer
registries. Starting from this set of recommendations we started to match needs and
available technologies. Development took place in adherence to international
standards of medical documentation and communication. Implementation and
Evaluation phases were conducted with assistance of other clinical researchers,
research nurses and cancer registrars.
Results: The analysis phase stated that cancer registries can be improved using
interoperability, semantic and visual data entry, client & server side-validation,
real-time analysis, rich presentation, tagging, social integration, data mining and
artificial intelligence technologies that are offered by current Internet era.
. Delivery for mobile phones with intelligent validation and interpretation facilitated
the portability of the system. Integration with knowledge bases added a decision
support property to cancer registry with providing real-time reports and diagrams
plotted over demographic maps. Usability was enhanced by providing user-friendly
interfaces.
Conclusions: Cancer registries have potential stunning future by gaining benefit
from the recent web technologies. Research on improving cancer information systems
should go hand in hand with continuous internet revolution.
Disclosure: All authors have declared no conflicts of interest.
1377P BURDEN OF SKELETAL-RELATED EVENTS (SRES) IN
PATIENTS (PTS) WITH SOLID TUMORS: RESULTS OF THE
STARS OBSERVATIONAL STUDY IN THE US VS EU
I. Duran 1 , A. Mahmood 2 , H. Hoefeler 3 , H. Ghazal 4 , D. Lueftner 5 , M. Fink 6 ,
A. Bahl 7 , G. Hechmati 8 ,R.Wei 9 , C. Atchison 10
1 Departamento de Oncologia, Hospital Madrid Norte San ChinarroCentro
Integral Oncologico Clara Campal, Madrid, SPAIN, 2 Cancer Specialists of South
Texas, Corpus Christi Cancer Center, Corpus Christi, TX, UNITED STATES OF
AMERICA, 3 Forschungszentrum Ruhr, Klifocenter, Witten, GERMANY,
4 Oncology, Kentucky Cancer Clinic, Hazard, KY, UNITED STATES OF AMERICA,
5 Oncology, Universitätsmedizin Berlin, Berlin, GERMANY, 6 Oncology, Orange
Coast Memorial Medical Center, Fountain Valley, CA, UNITED STATES OF
AMERICA, 7 Clinical Oncology, Bristol Haematology and Oncology Centre, Bristol,
UNITED KINGDOM, 8 International Health Economics, Amgen (Europe) GmbH,
Zug, SWITZERLAND, 9 Global Biostatistical Science, Amgen, Inc., Thousand
Oaks, CA, UNITED STATES OF AMERICA, 10 Global Health Economics, Amgen,
Inc., Thousand Oaks, CA, UNITED STATES OF AMERICA
Background: The STARS study was a prospective, multicenter, international,
observational study designed to measure the burden of SREs (radiation or surgery to
bone, pathologic fracture, or spinal cord compression) in pts with advanced cancer
and bone metastases. Here we report results in pts with solid tumors by geographical
region for US vs EU (Germany, United Kingdom, Spain, and Italy).
Methods: This analysis included pts with bone metastases secondary to breast,
prostate, or lung cancer and ≥1 SRE in the 97 days before enrollment (05/08 – 05/
10). Data on SREs and health resource utilization (HRU), including inpatient stays,
outpatient visits, emergency room visits, nursing home/long-term care facility stays,
home health visits, procedures, and certain medications, were collected
retrospectively for the 97 days before enrollment and prospectively for up to 21
months. Investigators were responsible for attributing HRU to each SRE.
Results: US = 190 pts with 354 SREs; EU = 478 pts with 893 SREs. Baseline
demographics and disease characteristics were similar for US and EU. Inpatient stays
were more frequent in EU compared with US, and the length of stay was longer in
EU (table). Outpatient visits were more frequent in US vs EU, while emergency room
visits were similar between regions. Nearly every SRE was associated with a
procedure in both regions; however, the number of procedures per SRE was higher in
US, which was in part due to a much greater number of external beam radiation
procedures per SRE in US likely reflecting standard use of multi-fraction radiation.
Slightly more pts were receiving bisphosphonates at/before enrollment in US
compared with EU, and pts in US received IV bisphosphonates sooner than in EU.
Conclusion: The HRU burden of SREs was substantial in both US and EU. Some
regional differences were observed, particularly with respect to hospitalization, length
of stay, and time to receipt of IV bisphosphonates.
HRU US (n = 354)* EU (n = 893)*
Inpatient Stays (IS) Proportion of SREs with IS
Number/SRE
14.7% 29.5%
Mean 0.18 0.32
Median Length of Stay (days) 0.0 0.0
Mean 10.6 19.9
Median 7.0 17.0
Outpatient Visits (OV) Proportion of SREs
with OV Number/SRE
88.1% 74.1%
Mean 9.1 4.8
Median 9.0 2.0
Emergency Room Visits (ERV) Proportion of
SREs with ERV Number/SRE
4.0% 4.1%
Mean 0.05 0.04
Median 0.0 0.0
Inpatient/Outpatient Procedures (P)
Proportion of SREs with P Number/SRE
95.5% 96.4%
Mean 11.3 6.9
Median 12.0 5.0
Bisphosphate (BP) Use Proportion of pts
receiving oral or IV BP
70.0% 63.0%
at or before enrollment Time from diagnosis of
bone metastasis to first IV BP use (months),
median**
1.8 6.7
*n = number of SREs; **Kaplan-Meier estimate
Disclosure: I. Duran: Advisory Board Member, Amgen. A. Bahl: Advisory Board
member Amgen, Novartis. G. Hechmati: Employee of Amgen and owns Amgen
stock. R. Wei: Employee of Amgen and owns Amgen stock. C. Atchison: Employee
of Amgen and owns Amgen stock. All other authors have declared no conflicts of
interest.
1378P STATISTICAL CONSIDERATION OF BIASES IN
PROGRESSION-FREE SURVIVAL (PFS) RESULTING FROM
DIFFERENCES IN IMAGING SCHEDULES
T. Tanase 1 , C. Hamada 2 , H. Fujii 3 , N. Nakayama 4 , T. Denda 5 , T. Takayama 6 ,
T. Yoshino 7 , A. Ohtsu 7
1 Data Science, Taiho Pharmaceutical Co., Ltd, Tokyo, JAPAN, 2 Faculty of
Engineering, Tokyo University of Science, Tokyo, JAPAN, 3 Division of Clinical
Oncology, Jichi Medical University, Tochigi, JAPAN, 4 Department of
Gastroenterology, Kanagawa Cancer Center, Kanagawa, JAPAN, 5 Department
of Gastroenterology, Chiba Cancer Center, Chiba, JAPAN, 6 Department of
Gastroenterology and Oncology, University of Tokushima Graduate School,
Tokushima, JAPAN, 7 Department of Gastroenterology & Gi Oncology, National
Cancer Center Hospital East, Chiba, JAPAN
Backgroud: In the three PIII trials for metastatic colorectal cancer (mCRC) patients
who are refractory to standard chemotherapy: NCIC CTG CO.17 (NEJM
2007;357:2040-8), 20020408 (JCO 2007;25:1658-65), and CORRECT (2012
ASCO-GI, #LBA 385) trial, the median PFS (mPFS) were similar and the early part
of PFS curves overlapped between treatment groups regardless of significance.
Generally, experimental treatments can potentially have biomarkers in such cases.
However, we consider that the scheduling of imaging tests affects PFS evaluations.
Material and methods: We simulated PFS computationally under the assumptions
for mCRC patients in first (L1), second (L2), and third line (L3) as “True
Parameters” in the following table (show L3 only). In addition, we assumed that the
probability of unscheduled progression was 0 and 20%, and the imaging schedules
Volume 23 | Supplement 9 | September 2012 doi:10.1093/annonc/mds410 | ix449